Femasys vs Neuraxis
Neuraxis reported revenue of $4 million in fiscal 2025, 1.6 times Femasys' $2 million in fiscal 2025. Femasys' revenue grew 40.8% in its latest year, and Neuraxis' grew 32.9%. Femasys had an operating margin of -767.0%, against -219.4% at Neuraxis. Free cash flow was −$19 million at Femasys and −$6 million at Neuraxis.
Side by side
| Femasys | Neuraxis | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $4M |
| Revenue growth | 40.8% | 32.9% |
| Revenue growth a year, last 5 years | 18.1% | — |
| Gross margin | 62.0% | 84.2% |
| Operating margin | −767.0% | −219.4% |
| Net margin | −812.3% | −218.6% |
| Free cash flow | −$19M | −$6M |
| Free cash flow margin | −837.9% | −181.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 77.6% | 31.3% |
| Last close | $1.26 | $4.50 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $74,000, sold $0 | bought $1.4 million, sold $0 |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
FemasysNeuraxis
Operating margin
Percent of revenue
FemasysNeuraxis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
FemasysNeuraxis